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Metallothioneins (MTs) are proteins that function by metal exchange to regulate the
bioavailability of metals, such as zinc and copper. Copper functions in the brain to
regulate mitochondria, neurotransmitter production, and cell signaling. Inappropriate
copper binding can result in loss of protein function and Cu(I)/(II) redox cycling can
generate reactive oxygen species. Copper accumulates in the brain with aging and has
been shown to bind alpha-synuclein and initiate its aggregation, the primary aetiological
factor in Parkinson’s disease (PD), and other alpha-synucleinopathies. In PD, total tissue
copper is decreased, including neuromelanin-bound copper and there is a reduction
in copper transporter CTR-1. Conversely cerebrospinal fluid (CSF) copper is increased.
MT-1/2 expression is increased in activated astrocytes in alpha-synucleinopathies, yet
expression of the neuronal MT-3 isoform may be reduced. MTs have been implicated
in inflammatory states to perform one-way exchange of copper, releasing free zinc
and recent studies have found copper bound to alpha-synuclein is transferred to
the MT-3 isoform in vitro and MT-3 is found bound to pathological alpha-synuclein
aggregates in the alpha-synucleinopathy, multiple systems atrophy. Moreover, both MT
and alpha-synuclein can be released and taken up by neural cells via specific receptors
and so may interact both intra- and extra-cellularly. Here, we critically review the role of
MTs in copper dyshomeostasis and alpha-synuclein aggregation, and their potential as
biomarkers and therapeutic targets.
Keywords: Parkinson’s disease, α-synuclein, copper, multiple system atrophy, dementia with lewy bodies,
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INTRODUCTION
There is considerable interest in understanding the role of copper in the etiology of PD. Copper
homeostasis is disrupted in the PD brain. Furthermore, in vitro studies demonstrate that copper
can exacerbate alpha-synuclein aggregation (Carboni and Lingor, 2015; Davies et al., 2016). Recent
studies have indicated that MTs, one of the major copper regulatory proteins in mammalian cells,
may influence alpha-synuclein aggregation in a copper-dependentmanner (Adam et al., 2016). This
review provides an overview of recent literature describing the role of copper dyshomeostasis in PD
and the potential role of MTs in this process.
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Several neurodegenerative diseases, including PD, multiple
system atrophy (MSA), and dementia with Lewy bodies (DLB),
show abnormal folding and aggregation of the alpha-synuclein
protein correlating with death of neuronal cells (Barnham et al.,
2004; Barnham and Bush, 2008; Wong and Krainc, 2017).
The pathogenesis of these disorders is complex; a result of
the interplay between genetic susceptibility and environmental
factors (Dauer and Prezedborski, 2003; Chai and Lim, 2013).
PD is a chronic disease caused by the progressive degeneration
of dopaminergic neurons, affecting both motor and non-motor
functions (Lees et al., 2009; Jenner et al., 2013). Degeneration
progresses from the brain stem to the locus coeruleus, dorsal
and raphe nuclei, and ventral tegmental area to the prefrontal
cortex (Wirdefeldt et al., 2011; Jucker and Walker, 2013). Age is
the most significant risk factor (Dauer and Prezedborski, 2003),
but other factors include head trauma or injury and obesity
(Lees et al., 2009; Jenner et al., 2013). There are no diagnostic
biomarkers for PD, yet it is estimated that the pre-symptomatic
disease can extend over 10 years. PD can arise from autosomal
dominant mutations associated with the alpha-synuclein gene,
SNCA, resulting in A53T, H50Q, E46K, A53E, G51D, and A30P
variants (Wirdefeldt et al., 2011; Nussbaum, 2017) and has also
been linked to alpha-synuclein overexpression, accumulation
and aggregation (Shin et al., 2009; Anandhan et al., 2015; Van
der Perren et al., 2015). Recently, a point mutation within the
Vps35 subunit of the retromer was linked to PD which results in
disrupted trafficking of cathepsin D, a protease important for the
degradation of alpha-synuclein (Follett et al., 2014).
DLB is characterized by progressive dementia, hallucinations,
delusions and memory loss, rigidity, and postural disturbance
(Noe et al., 2004), with both PD and DLB characterized by
mostly neuronal alpha-synuclein deposits. A third prominent
alpha-synucleinopathy is MSA a condition which shows alpha-
synuclein inclusions mostly affecting glial cells (Spillantini and
Goedert, 2000). MSA is rapidly progressive and shares most of
its symptoms with PD, although degeneration occurs both to the
central nervous system and periphery (Jellinger, 2014; Radford
et al., 2014).
Current treatments for PD do not cure the underlying
condition but alleviate symptoms (Dauer and Prezedborski,
2003; Jankovic, 2012; Jenner et al., 2013). Dopamine
replacement therapy via the precursor L-DOPA (L-3,4-
dihydroxyphenylalanine) is the most prevalent treatment
(Jankovic, 2012). However, patients develop resistance to L-
DOPA over time (Connolly and Lang, 2014) and prolonged
treatment may eventually accelerate deterioration due to
generation of reactive oxygen species (Barnham et al., 2004;
Thanvi and Lo, 2004), whereas, pre-treatment with non-steroidal
anti-inflammatories was found to be effective in animal PD
models (McCarty, 2006; Pinto et al., 2016). The development of
Abbreviations:AD, Alzheimer’s disease; ALP, autophagy lysosomal pathway; ANS,
autonomic nervous system; CSF, cerebrospinal fluid; DLB, Dementia with Lewy
bodies; MPTP, 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (chemical); MSA,
Multiple systems atrophy; MT, metallothionein; PD, Parkinson’s disease; ROS,
reactive oxygen species; SNpc, substantic nigra, pars compacta; UPS, ubiquitin
proteasome system.
mechanism-based therapeutics and neuroprotective strategies,
including metal chelation, is a focus of on-going research (Hart
et al., 2009).
LEWY BODIES AND ALPHA-SYNUCLEIN
In PD pathology there is an accumulation of alpha-synuclein
in the brain stem, spinal cord, and cortex (Lees et al., 2009),
primarily in the form of intra-neuronal aggregates (Lewy bodies,
LB) composed mostly of alpha-synuclein. Other aggregate
proteins including Parkin, PINK-1, DJ-1, and LRRK-2 gene
products relate to pathways such as autophagy/mitophagy
processes, oxidative stress mechanisms, and mitochondrial
survival (Shin et al., 2009). Alpha-synuclein makes up 1% of
total brain soluble proteins in humans (Stefanis, 2012), with
putative functions in dopamine production, uptake and storage
as well as recycling of neurotransmitter vesicles (Sidhu et al.,
2004; Marques and Outeiro, 2012; Stefanis, 2012). It is a small
protein (14 kDa) existing as an unfolded monomer (Vekrellis
et al., 2004; Cremades et al., 2012), although recent work has
revealed that it is also present in oligomeric forms (Yates, 2011).
Studies on alpha-synuclein knockout mice implicate its role in
neurotransmitter regulation (Yavich et al., 2004). The protein
may also act as a calcium channel activator and mediator of
calcium entry and may increase cell toxicity from oxidative
stress (Dryanovski et al., 2013; Rcom-H’cheo-Gauthier et al.,
2016).
Current evidence shows alpha-synuclein oligomerizes and
forms aggregates within the neuronal cytoplasm that have a
deleterious outcome for the neuron and provide a link to
neurotoxicity (Vekrellis et al., 2004; Chen and Feany, 2005;
Stefanis, 2012). The inhibition of normal cellular function by
alpha-synuclein aggregates leads to increased oxidative stress
(Cremades et al., 2012), and overexpression of alpha-synuclein
caused protein degradation malfunction phenotype in rats (Kirik
et al., 2002; Vekrellis et al., 2004). It is unclear whether LB
are neurotoxic or neuroprotective. They may be formed to
sequester aberrant proteins that would otherwise be neurotoxic.
Drosophila melanogaster models of PD have demonstrated that
increased inclusion body formation is associated with a reduction
in overall toxicity to neuronal cells (Chen and Feany, 2005).
Similarly, rat models with inhibition of proteasome function
show a rise in aggregates but cessation of neuronal death
(Sawada et al., 2004). Although several recent reports indicate
that LBs are neurotoxic, contributing to cell death in vivo
with decreased mitochondrial and proteosomal function which
causes increased oxidative stress and cell death (Branco et al.,
2010). Alternatively, other studies suggest an inverse correlation
between cell viability and the quantity of LB-like alpha-synuclein
inclusion bodies (Wan and Chung, 2012). Recently, alpha-
synuclein has been observed to propagate between neurons,
whereby alpha-synuclein spread mimicked the progression of
neurodegeneration observed in PD from the substantia nigra
toward the frontal cortex (Luk et al., 2012). This propagation of
alpha-synuclein resembles prion disease spread, where infectious
proteins travel between host cells (Jucker and Walker, 2013;
Valdinocci et al., 2017).
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COPPER AND α-SYNUCLEIN DISEASE
Copper is an essential element, mainly as a catalytic center
of several enzymes involved in mitochondrial energy
transformation, the synthesis of neurotransmitters, cell signaling,
and other crucial processes. It accumulates in the brain with
aging (Zatta et al., 2008; Vasudevaraju et al., 2010; Pushkar et al.,
2013) and has been shown to bind alpha-synuclein and initiate
its aggregation (Paik et al., 1999; Rose et al., 2011; Carboni and
Lingor, 2015). At physiological pH, two copper(II) binding sites
exist on alpha-synuclein corresponding to M1-D2, and H50.
However, at pH 5.0, the H50 binding is strongly diminished and
alpha-synuclein additionally showed a completely different site
for copper binding at D119–E123 (Drew et al., 2008; De Ricco
et al., 2015a). Two regions have been shown to bind to copper(I):
M1–M5 and M116–M127 (Camponeschi et al., 2013) with M1–
M5 being the stronger and thus more relevant (Figure 1). Within
the cell, both copper species co-exist and the transition from
copper(II) to copper(I) in amyloid aggregates was suggested to
contribute to the presence of ROS leading to cell damage (Miotto
et al., 2014). The capacity of copper to bind to alpha-synuclein
at H50 could also be highly relevant for disease pathology in
humans. Indeed, the point mutation H50Q which leads to a
familial form of PD corresponds to the major copper(II) binding
site (Proukakis et al., 2013) and binding of copper(II) to this
mutant results in a structurally different species compared to
the copper-WT species (Villar-Piqué et al., 2016). The ability
of copper to accept or donate electrons implicates it in the
production of ROS in PD (Barnham et al., 2004; Barnham and
Bush, 2008; Valensin et al., 2016), and it has more recently been
shown that in the SN, total tissue copper is decreased (Montes
et al., 2014). Moreover, some studies have found an increase of
serum copper, and indeed a positive correlation between high
concentration levels and severity of the disease (Brewer, 2009;
Arnal et al., 2010). Furthermore, free copper levels, both in
PD cases and DLB cases, were found to have increased in the
cerebrospinal fluid (CSF) (Pall et al., 1987; Magaki et al., 2007;
Hozumi et al., 2011).
Copper in extracellular fluid bound to copper-binding
proteins, such as ceruloplasmin, is less harmful than the free,
or loosely bound ions (Squitti et al., 2016). These metal-binding
proteins act to sequester the reactive metal and most copper
present in brain tissue is bound to transport carriers or other
proteins (Davies et al., 2013; Squitti et al., 2016). Davies et al.
found that neuromelanin-bound copper in the SN of PD patients
decreased, suggesting increased free copper linked to neuronal
death. It was also found that the copper transporter CTR-1
becomes drastically reduced in the SN of PD brain before regional
cell loss begins (Davies et al., 2014). Intracellular copper levels
are regulated by the action of membrane copper-ATPases (Cu-
ATPases) that pump copper. Genetic mutation of Cu-ATPase
(ATP7A) has been found to cause diseases of copper deficiency
in the brain and the specific mutation of ATP7B results in
diseases of copper accumulation (Lutsenko et al., 2007; Choi and
Zheng, 2009; Davies et al., 2016). Recent work has examined
copper chelation as a means to reduce free-radical damage, with
clioquinol (a metal chelator) shown to reduce aggregation of
FIGURE 1 | (A) Sequence alignment showing alpha-synuclein copper binding
ligands overlap with PD-linked H50 mutation in membrane binding domain.
Red represents the known point mutations in familial Parkinson’s disease in
alpha-synuclein. Yellow represents the KTK repeats in the N-terminus which
are involved in lipid interaction. (B) Immunofluorescence shows MT-3
co-localizes with alpha-synuclein in glial cytoplasmic inclusions in MSA brain
tissue. (C) MT-3 associates with alpha-synuclein filaments in isolated
alpha-synuclein inclusions by immunogold-labeling (black dots; arrows)
(Pountney et al., 2011).
beta-amyloid and alpha-synuclein in transgenic mice (Cherny
et al., 2001; Adlard et al., 2008; Finkelstein et al., 2016).
Metallothioneins (MT), contribute to copper regulation and may
also act as ROS absorbers (Carter et al., 1984; Otsuka, 2004;
Lutsenko et al., 2007). Additionally, MTs have been implicated
in MSA (Hozumi, 2013) and the MT-3 isoform was found to co-
localize with alpha-synuclein and coat alpha-synuclein filaments
in the hallmark glial alpha-synuclein deposits (Figures 1B,C;
Pountney et al., 2011). Furthermore, MT-3 was found to inhibit
ROS production by copper-alpha-synuclein by a metal-swap
mechanism (Meloni and Vašák, 2011).
METALLOTHIONEINS
MTs, are small (6–7 KDa) native Zn/Cd binding proteins
(Margoshes and Vallee, 1957; Kägi and Vallee, 1960), composed
of cysteine-metal cores that have a high affinity for copper
(Pountney et al., 1995; Nordberg, 1998; Hozumi et al., 2004;
Carpenè et al., 2007; Dong et al., 2015). MT-knockout mice
become extremely susceptible to the effects of environmental
stress, including copper-exposure (West et al., 2008; Manso et al.,
2011; Petro et al., 2016). MTs occur in two major isoforms:
MT-1/2 and MT-3 (Nordberg, 1998), with MT-1/2 present
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throughout the body, while MT-3 is present primarily in the
brain (Palmiter et al., 1992). MT-3 differs by a unique acidic
insert comprised of six amino acids and two Pro substitutions
and has an observed ability to inhibit cell growth in cultured
neurons (Palmiter et al., 1992; Chung et al., 2003; Howells et al.,
2010). Recent work showed MT to be neuroprotective against
proteinopathies in neurodegenerative disease, a finding which
is reinforced by low MT-3 levels in neurons of Alzheimer’s
patients compared to healthy individuals (Kimura and Itoh,
2008; Howells et al., 2010; Uchida, 2010). Interestingly, this same
deficiency is seen in PD, although this finding may be somewhat
controversial (Hozumi et al., 2004). Previous work showed that
MTs were more highly expressed in Parkinsonian astrocytes
(Michael et al., 2011) and also in astrocytes in MSA (Pountney
et al., 2011).
MTs bind copper with high affinity, suggesting a role in copper
homeostasis (Chung et al., 2008, 2010), and mice displaying
copper overload crossed with an MT 1/2 knockout did not
survive past infancy (Kelly and Palmiter, 1996). Exchange
between protein and metal has been observed in studies that
found MTs prevented copper-induced aggregation of amyloid
beta peptide or alpha-synuclein (Meloni et al., 2008; Meloni and
Vašák, 2011; De Ricco et al., 2015b). The MT gene promoter
contains a metal response element (Richards et al., 1984; Sadhu
and Gedamu, 1989; West et al., 1990; Pountney et al., 1995),
although the MT-3 isoform does not show metal inducibility
(Faller, 2010). The cysteine-rich structure and metal-response
element of MTs implicate a possible target for attenuating
copper-induced aggregation of alpha-synuclein (West et al.,
2008; Waldron et al., 2009). Copper-MT may also represent a
potential biomarker for Parkinson’s or Alzheimer’s disease as
MT levels increase in response to zinc, copper, or cadmium
and physiological stress (Richards et al., 1984). MTs have been
found to be recruited to alpha-synuclein aggregates in MSA
(Figures 1B,C; Pountney et al., 2011). Other studies have shown
that exogenous MT is readily taken up by neuronal cells and
identified that neurons take upMT through the megalin receptor
(Fitzgerald et al., 2007; Chung et al., 2008). Indeed, alpha-
synuclein may also be taken up by neural cells or may interact
extracellularly with MT.
OXIDATIVE STRESS AND
NEUROINFLAMMATION
Oxidative stress results from incomplete reduction of oxygen
resulting in the formation of reactive oxygen species (ROS)
and/or a decrease in the degradation of these species by
endogenous anti-oxidant systems (Halliwell, 2001; Sas et al.,
2007). It is unknown whether oxidative stress damage is a
prerequisite of PD pathogenesis, or the result of the disease itself
(Blesa et al., 2015). Autosomal recessive mutations involving
the Parkin gene inhibit its function as a ubiquitin ligase,
affecting protein degradation and turnover mechanisms, as well
as mitophagy. This may be an important factor as mitochondrial
dysfunction leads to oxidative stress (Kitada et al., 1998;
Siddiqui et al., 2016). Additionally, PINK1 disruption results
in loss-of-function of mitophagic systems. Mutations in DJ-1
similarly disrupt cellular oxidative stress responses and protein
degradation systems (Shin et al., 2009). Moreover, MTs were
found as effective ROS scavengers in a PD animal model (Ebadi
et al., 2005; Ebadi and Sharma, 2006). MTs are capable of self-
protection through maintenance of copper and zinc levels and
they also directly protect against ROS (Shiraga et al., 1993).
Recently, MTs were shown to inhibit the formation of inclusion
body-like structures, Charnoly bodies, mitochondrially formed
electron-dense membrane stacks found in neurons, leading to
a lower observed incidence of alpha-synucleinopathies (Sharma
et al., 2013b; Sharma and Ebadi, 2014a,b). The scavenging ability
of MTs to combat ROS leads to a lowering of oxidative stress and
therefore a potential role in neuroprotection against PD (Ebadi
et al., 2005; Ebadi and Sharma, 2006; Hozumi, 2013).
Neuroinflammation has been linked to alpha-
synucleinopathies and there is evidence of a role of MTs in
inflammation in brain injury (Chung et al., 2009; Pedersen et al.,
2009; Shastri et al., 2013; Vieira et al., 2015). MTs have been
implicated in inflammatory states and act as exchangeable zinc
stores which can swap with toxic metals, such as copper and
cadmium (Rofe et al., 1992; Meloni et al., 2008). Astrocytes, the
primary cell type expressing MT-1/2 in the brain, up-regulate
MT-1/2 expression as a physiological response which may
promote neuroregeneration as well as survival (Chung et al.,
2008; Landowski et al., 2016). Treatment with MT-2 attenuated
the immune response of neurotoxic quinolinic acid production in
brain injury (Chung et al., 2009). More recently, overexpression
ofMT-1 in amousemodel of AD promoted reversal in behavioral
symptoms of disease and more inert soluble amyloid species
(Manso et al., 2016). Indeed, extracellular alpha-synuclein
inhibits β-amyloid plaque formation (Bachhuber et al., 2015), a
process that may also be influenced by extracellular MT binding
(De Ricco et al., 2015b). Further, in a mouse model of AD,
MT-3- and MT-1/2-deficient mice had lower plaque burdens
and mortality, and performed better in behavioral tests (Manso
et al., 2012a,b). Figure 2 summarizes the interplay between MT,
alpha-synuclein and copper in different cell types in PD.
BIOMARKER AND THERAPEUTIC
POTENTIAL OF METALLOTHIONEIN
The presence of LB post-mortem is the only diagnostic marker
for PD (Beach et al., 2013; Sharma et al., 2013a; Espay et al.,
2017), although symptoms, such as tremor and rigidity appear
after significant damage has already occurred (Jankovic, 2012;
Connolly and Lang, 2014). Serum MT levels are significantly
increased in pathological conditions including various cancer
types (Krizkova et al., 2010) and following traumatic brain injury
(Kukacka et al., 2006) and MT can traverse the glomerular
apparatus into the urine from the blood supply, with the
megalin receptor for MT-1/2 present in the choroid plexus
(Lewis et al., 2012). The potential of MT as a biomarker has
been speculated in lysosomal storage disorders with nervous
system involvement and leukodystrophy (LSDs-LD), where
increased white matter MT expression correlated to severity and
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FIGURE 2 | Schematic representation of copper, MT, α-syn interactions in PD. MT-1/2 expression is primarily astrocytic in the brain, whereas MT-3 is neuronal.
MTs and alpha-synuclein may interact either intra- or extracellularly, either directly or indirectly. Copper induces alpha-synuclein aggregation, whereas MT’s chelate
copper. Copper binding to alpha-synuclein generates ROS, whereas MTs are powerful anti-oxidants.
progression of LSDs-LD and may be related to inflammation
and oxidative stress (Cesani et al., 2014). Increased astrocytic
MT expression in MSA may similarly point to the biomarker
potential of MT in alpha-synuclein disease (Pountney et al.,
2011). Indeed, MT is internalized by neural cells via the low-
density lipoprotein receptor-related protein receptor, LRP-1,
one of the primary trans-membrane transporters involved in
the transfer of molecules out of the brain, suggesting that
MT might be actively shuttled into the blood (Landowski
et al., 2016). Exposure of rodents to heavy metals, such as
copper resulted in substantial accumulation of Cu-MT in
the liver and kidneys (Kurasaki et al., 1998) suggesting that
copper-loaded rather than the natural Cu/Zn-loaded protein
in serum or urine could provide a biomarker of copper-
imbalance.
Glucocorticoids are regulators of MTs, particularly during
fetal development (Quaife et al., 1986) and have been shown
to produce increased MT levels in animals (Klaassen, 1981).
Dexamethasone is a potent inducer of MT (Karin et al., 1980;
Palmiter et al., 1992; Méndez-Armenta et al., 2003), although less
effective than heavy metals (Kobayashi et al., 1985), increasing
MT-1 mRNA synthesis five-fold (Mayo and Palmiter, 1981) by
acting on the glucocorticoid response element in the promoter
(Karin et al., 1984; Richards et al., 1984). Dexamethasone, is also
neuroprotective via MT induction in an ALS model (Tokuda
et al., 2015) and conserved dopamine content by 20% in a PD
model (Kurkowska-Jastrzebska et al., 2004). It is tempting to
speculate that MT induction could have therapeutic potential in
alpha-synuclein diseases.
CONCLUSION
MTs may offer neuroprotection in alpha-synucleinopathies,
however, further studies are needed to determine if the
neuroprotective action is mediated via copper chelation or
is associated with ROS scavenging, neuroinflammation or
neurotrophic effects, if MT and alpha-synuclein interact directly
or indirectly and if this is intra- or extracellular.
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